Oragenics (NYSE:OGEN) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report released on Monday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Up 1.0 %

NYSE OGEN opened at $0.29 on Monday. The firm has a market cap of $3.49 million, a P/E ratio of -0.04 and a beta of 0.38. Oragenics has a 52-week low of $0.25 and a 52-week high of $3.50. The business’s 50-day moving average price is $0.32 and its 200 day moving average price is $0.47.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.